Despite decades of laboratory, epidemiological and clinical research, breast cancer
incidence continues to rise. Breast cancer remains the leading cancer-related cause of …

Abstract The European Collaborative on Personalized Early Detection and Prevention of
Breast Cancer (ENVISION) brings together several international research consortia working …

Breast cancer is the most frequently diagnosed cancer in women, with estrogen receptor
positive (ER+) breast cancer making up approximately 75% of all breast cancers diagnosed …

The translational challenges in the field of precision oncology are in part related to the
biological complexity and diversity of this disease. Technological advances in genomics …

ABSTRACT A hereditary predisposition to breast cancer significantly influences screening
and follow-up recommendations for high-risk women. However, in patients with a suggestive …

Background Four previously published randomised clinical trials have shown that tamoxifen
can reduce the risk of breast cancer in healthy women at increased risk of breast cancer in …

Background Tamoxifen and raloxifene reduce the risk of breast cancer in women at elevated
risk of disease, but the duration of the effect is unknown. We assessed the effectiveness of …

Atypical Hyperplasia of the Breast — Risk Assessment and Management Options | New England
Journal of Medicine Skip to main content The New England Journal of Medicine homepage …

For more than 25 years, tamoxifen has been the gold standard for the endocrine treatment of
all stages of oestrogen-receptor-positive breast cancer, and the World Health Organization …

ContextTamoxifen is approved for the reduction of breast cancer risk, and raloxifene has
demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis …